Posts Tagged ‘liver’

Tuesday April 12th, 2016

Drs. Bruix and Gracia-Sancho, awarded by the EASL for their research on liver diseases

Dr. Jordi Gracia-Sancho, researcher from the Hepatic hemodynamics and portal hypertension IDIBAPS team and from CIBERehd, and Dr. Jordi Bruix, head of the Hepatic Oncology Unit of Hospital Clínic and IDIBAPS and scientific director of CIBERehd, will be awarded by the European Association for the Study of the Liver (EASL) in recognition of their scientific career. Dr. Gracia-Sancho has been awarded with the Young Investigator Award in Hepatology 2016 and Dr. Bruix receives the recognition for his entire scientific career. The awards will be presented in the framework of the International Liver Congress, organized by the EASL and held between 13 and 17 April in Barcelona. These awards are a prestigious recognition to the research carried out to date by both researchers in the field of liver diseases.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Friday January 22nd, 2016

A nutritional combination of saturated fatty acids can induce steatohepatitis

Researchers from the IIBB-CSIC and IDIBAPS have published an article in Oncotarget journal in which they have shown for the first time that diets enriched in two types of saturated fatty acids – palmitic and myristic – induce the development of steatohepatitis, an advanced stage of the fatty liver disease, and promotes fat to accumulate in the liver which causes inflammation. The coordinators of this study are Dr. Jose C. Fernández-Checa, Head of the Mitochondrial Regulation of Cell Death and Steatohepatitis IDIBAPS team, and Dr. Carmen García-Ruiz, researcher at the same team. Dr. Laura Martinez, post-doctoral researcher at Dr. Fernández-Checa’s group, is the first author of the study.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday February 19th, 2013

Notch signaling promotes liver carcinogenesis becoming an appealing target for new therapies

Less than 30% of newly diagnosed hepatocellular carcinoma (HCC) patients are eligible for curative therapies such as resection, liver transplantation, or local ablation. Hence, there is an increasing need to develop new drugs for a disease that, besides being the third leading cause of cancer death worldwide, has tripled its incidence in the last decades in the United States. An article published in Gastroenterology by the IDIBAPS Translational Research in Hepatic Oncology group, led by the ICREA investigator Prof Josep Maria Llovet, demonstrates that Notch signaling is activated in a subset of human HCC samples, and promotes liver tumor formation in genetically engineered mice. In addition, the study reports a Notch gene signature able to predict response to Notch inhibition in experimental models of liver cancer. First authorship of the manuscript is shared by Dr Augusto Villanueva and Clara Alsinet . The study is the result of an international collaboration that includes renown leaders in the field from the University of Pennsylvania (Philadelphia), the Broad Institute and Dana-Farber Cancer Institute at Harvard Medical School (Boston), and Mount Sinai School of Medicine (New York).

Read the rest of this entry »

Comments Closed